참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | Erythromycin | HCID 12560 | — |
| 반응물 | Sodium Bicarbonate | HCID 516892 | — |
| 반응물 | Erythromycin - Impurity F | HCID 9875064 | — |
| 용매 | Acetic Acid | HCID 176 | — |
| 생성물 | Erythromycin A enol ether | HCID 83954 | — |
반응 단계
Synthesis of EM701 was disclosed in detail in WO 02/14338 A1. A glacial acetic acid solution of erythromycin was stirred at room temperature for 2 hours, and aqueous sodium hydrogencarbonate solution was slowly added and neutralized. The reaction mixture was extracted with chloroform. The organic layer was dehydrated by adding anhydrous sodium sulfate, which was removed off by filtration to obtain crude product. The crude product was purified by silica gel column chromatography with chloroform-methanol-aqueous ammonia (10:0.5:0.01→10:1:0.05) to obtain erythromycin A enol ether. Potassium carbonate was added to methanol solution of erythromycin A enol ether and refluxed for 2 hours. After solvent was removed, the residue was dissolved in aqueous sodium hydrogencarbonate and the mixture was extracted with chloroform. The extract was dehydrated with sodium sulfate, filtered and distilled off. The obtained crude product was purified by silica gel column chromatography with chloroform-methanol-aqueous ammonia (10:0.5:0.01→10:1:0.05) to obtain EM701 (white powder).
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| 특허 번호 | US07521428B2 |
|---|
| 출처 데이터셋 | uspto-grants-2009_04 |
|---|
| ORD ID | ord-20f04dbbc9e74f7280d839e3ca439e37 |
|---|
| 출처 메모 | uspto-grants-2009_04 |
|---|